[Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].

The treatment of acute lymphoblastic leukemia (ALL) in childhood and adolescence achieves nowadays cure rates of more than 80%. The detection of minimal residual disease (MRD) via molecular genetic methods provides - in comparison with conventional clinical and biological parameters - much more sensitive approaches to monitor individual treatment response. Here we will discuss the molecular background and technical developments in the framework of the BFM-study group.
(© Georg Thieme Verlag KG Stuttgart · New York.)